Abstract 1546P
Background
Prostaglandin E2 (PGE2) and its receptor EP4 showed immunosuppressive activity in cancers. In the ONO-4578-01 phase I study parts A/B, ONO-4578 (4578), which is an antagonist of EP4, alone and in combination with nivolumab (NIV) demonstrated a manageable safety profile in patients (pts) with advanced or metastatic solid tumors (Cancer Sci. 2023;114:211-220). Part C evaluated the safety, preliminary efficacy, and biomarkers of 4578 + NIV in pts with gastric or gastroesophageal (G/GEJ) cancer.
Methods
Part C was conducted at 22 sites in Japan, and it included pts with unresectable advanced or recurrent G/GEJ cancer who previously received at least two regimens. We categorized pts into three groups: IO-treated, pts who received immune-oncology (IO) treatment with anti-PD-(L)1 antibody as the most recent treatment; IO-naïve, pts without IO treatment; UGT1A1p, pts with UGT1A1 polymorphism. Pts received oral 4578 (40 mg) daily and NIV (480 mg) every 4 weeks. The primary endpoint was safety. We assessed biomarkers with multiple methods including immunostaining and RNA-seq using pts’ tumor tissues, and urine PGE2 metabolite (PGEM) analysis.
Results
The IO-treated, IO-naïve, and UGT1A1p groups included 30, 30, and 6 pts, respectively, with a median age of 65.0 years. Treatment-related adverse events (TRAEs) occurred in 46 (70%) pts, wherein grade ≥3 TRAEs occurred in 17 (26%). No pts died due to TRAEs. Tolerability was confirmed in UGT1A1p. The investigator-assessed objective response and disease control rates were 10% and 73% in IO-treated and 17% and 40% in IO-naïve, respectively. Of note, >50% of the IO-treated pts achieved tumor shrinkage. In biomarker analyses, we observed signs of activated immune status in the tumor microenvironment after treatment, such as increases in T cell signature score and number, and relative increase of the ratio of M1 macrophage signature score to that of M2. Baseline urine PGEM, the potential surrogate marker of tumor PGE2, was higher in pts with PR or SD than in pts with PD, suggesting the contribution of 4578 to the antitumor activity.
Conclusions
4578 + NIV demonstrated a manageable safety profile and antitumor activity in pts with G/GEJ cancer.
Clinical trial identification
NCT03155061.
Editorial acknowledgement
Drafting by Kumiko Yoshioka, PhD, of Ono Pharmaceutical.
Legal entity responsible for the study
The authors.
Funding
Ono Pharmaceutical Co., LTD.
Disclosure
H. Hirano: Financial Interests, Personal, Invited Speaker: Taiho Pharmaceutical, Ono Pharmaceutical, Teijin Pharma, Nichi-Iko, Novartis; Financial Interests, Institutional, Research Grant: Chugai Pharmaceutical, Daiichi Sankyo, Taiho Pharmaceutical, Ono Pharmaceutical, Janssen Pharmaceutical, Merck Biopharma, Bristol Myers Squibb, Pfizer, Eisai, Amgen, Astellas, Seagen, MSD, Insyte, BeiGene, Novartis. A. Kawazoe: Financial Interests, Personal, Advisory Board: Zymeworks; Financial Interests, Personal, Invited Speaker: Taiho Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Limited, Eli Lilly, Bristol Myers Squibb, Ono Pharmaceutical Co., Ltd.; Financial Interests, Personal, Expert Testimony: Merck & Co. K. Yamaguchi: Financial Interests, Personal, Invited Speaker: Taiho Pharm; Financial Interests, Personal, Expert Testimony: Daiichi Sankyo, Bristol Myers Squibb, Ono Pharm, Eli Lilly Japan; Financial Interests, Institutional, Funding: Taiho Pharm. T. Hamaguchi: Financial Interests, Institutional, Local PI: Ono Pharmaceutical Co., Ltd.; Other, Other, honorary: Ono Pharmaceutical Co., Ltd. Y. Narita: Financial Interests, Personal, Invited Speaker: Yakult, Taiho, Eli Lilly, Daiichi Sankyo, Ono, BMS; Financial Interests, Personal, Advisory Board: Daiichi Sankyo; Financial Interests, Institutional, Invited Speaker: Ono pharma, BMS, AstraZeneca, Daiichi Sankyo. H. Hara: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, Boehringer Ingelheim, MSD; Financial Interests, Personal, Invited Speaker: Daiichi Sankyo, MSD, Ono, Bayer, Chugai, Lilly, Merck Biopharma, Taiho, Takeda, Yakult, Bristol Myers Squibb; Financial Interests, Institutional, Invited Speaker: Amgen, Astellas, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Chugai, Daiichi Sankyo, Dainippon Sumitomo, Janssen, Merck Biopharma, MSD, Ono, Taiho, ALX Oncology. Y. Hamamoto: Financial Interests, Institutional, Invited Speaker: Ono Pharmaceutical Company. T. Esaki: Financial Interests, Personal, Invited Speaker: Chugai, Taiho, EP force, MSD, Daiichi Sankyo, Eli Lilly, Ono, Bristol; Financial Interests, Institutional, Research Grant: MSD, Novartis, Ono, Nihon Kayaku, IQVIA, Daiichi Sankyo, Chugai, Syneos Health Clinical, Pfizer, Dainippon Sumitomo, Quintiles, Eli Lilly, Parexel, Astellas, Astellas Amgen Biopharma, Eisai, Bayer, Asahikasei Pharma; Financial Interests, Institutional, Funding: Chugai, Nihon Kayaku. All other authors have declared no conflicts of interest.
Resources from the same session
1521P - Addition of durvalumab to CROSS in oesophageal adenocarcinoma is feasible and safe
Presenter: Hans Schloesser
Session: Poster session 21
1523P - Phase II dose optimization results from MOUNTAINEER-02: A study of tucatinib, trastuzumab, ramucirumab, and paclitaxel for HER2+ gastroesophageal cancer (GEC)
Presenter: Mustapha Tehfe
Session: Poster session 21
1524P - First-line TST001 plus capecitabine and oxaliplatin (CAPOX) for advanced G/GEJ cancer with CLDN18.2 positive overall survival data from study transtar102-Cohort C
Presenter: Lin Shen
Session: Poster session 21
1526P - Phase Ib results of bemarituzumab (BEMA)+mfolfox6+nivolumab (NIVO) for advanced gastric/gastroesophageal junction cancer (G/GEJC): Fortitude-102 part 1
Presenter: Zev Wainberg
Session: Poster session 21
1527P - Efficacy and safety of infigratinib in locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma patients with FGFR2 gene amplification
Presenter: Jiajia Yuan
Session: Poster session 21
1528P - A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors
Presenter: Daniel Olson
Session: Poster session 21
1529P - Tislelizumab plus chemotherapy sequential neo-chemoradiotherapy therapy as total neoadjuvant therapy in locally advanced esophageal squamous cell carcinoma (ETNT)
Presenter: Wenwu He
Session: Poster session 21
1530P - Health-related quality of life (hrqol) in patients with claudin-18 isoform 2-positive (CLDN18.2+) locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma: Results from SPOTLIGHT and GLOW
Presenter: Florian Lordick
Session: Poster session 21